Avalyn Pharma

AVLN · Nasdaq Filing snapshot

Avalyn Pharma is a clinical-stage biopharma developing inhaled formulations of approved oral medicines for serious respiratory diseases. Its lead candidates, AP01 and AP02, are inhaled versions of pirfenidone and nintedanib — the two approved oral drugs for progressive pulmonary fibrosis — delivered through PARI's eFlow nebulizer to raise lung exposure and cut systemic side effects. The company has not generated revenue. Its $18.00 Nasdaq IPO raised $300M gross. The filing names the approved-drug makers Boehringer Ingelheim (Ofev) and Genentech/Roche (Esbriet), plus a deep pipeline field including Pliant, Insmed, Bristol Myers Squibb and others.

Listed

Apr 30, 2026

Raised

$300M

Sector

Biotechnology · Respiratory · Pharmaceuticals

Named rivals

15 in the S-1

Named in the S-1 12 of 15 shown

Avalyn Pharma

AVLN · the filer

Boehringer Ingelheim

named 11×

Roche

named 5×

Pliant Therapeutics

named 4×

Mediar Therapeutics

named 4×

Genentech

named 3×

Legacy Pharma

named 3×

Insmed

named 1×

Bristol Myers Squibb

named 1×

Endeavor Biomedicines

named 1×

Vicore Pharma

named 1×

United Therapeutics

named 1×

Eli Lilly

named 1×

“

The read

Reformulates the two approved IPF drugs as inhaled versions — so it competes head-on with the makers of Ofev (Boehringer Ingelheim) and Esbriet (Roche/Genentech) using their own molecules, against a pipeline of a dozen more. Clinical-stage, no revenue; a $300M raise.

Want the full picture on Avalyn Pharma?

Request the deep Exposure Report — share-of-presence, a 90-day signal timeline, and the white space these 15 rivals leave open. We build it within 48 hours.

Request full coverage